A 2-year-old girl is brought to the pediatric clinic with a history of failure to thrive, developmental delay, and recurrent infections. Laboratory investigations reveal elevated plasma ammonia (180 μmol/L), normal blood glucose, and normal plasma amino acid profile. Urine orotic acid is markedly elevated. Genetic testing confirms a deficiency in ornithine transcarbamylase (OTC). Which of the following metabolic derangements BEST explains the elevated urinary orotic acid in this patient?

Explanation

## Understanding Orotic Aciduria in OTC Deficiency ### Pathophysiology of OTC Deficiency **Key Point:** Ornithine transcarbamylase (OTC) catalyzes the second step of the urea cycle, combining carbamoyl phosphate (CP) and ornithine to form citrulline. Deficiency leads to: - Accumulation of carbamoyl phosphate in the mitochondrial matrix - Severe hyperammonemia (ammonia cannot be incorporated into the urea cycle) - Elevated plasma glutamine and alanine (nitrogen scavenging) ### Why Orotic Acid Rises in OTC Deficiency Carbamoyl phosphate is a critical substrate at a metabolic crossroads: ```mermaid flowchart TD A[Carbamoyl Phosphate]:::outcome A -->|Urea Cycle| B[Citrulline]:::outcome A -->|De novo Pyrimidine Synthesis| C[Carbamoyl Aspartate]:::outcome C --> D[Dihydroorotate]:::outcome D --> E[Orotate]:::outcome E --> F[Orotidine Monophosphate]:::outcome F --> G[UMP]:::outcome style A fill:#ffcccc style E fill:#ffcccc ``` **High-Yield:** In OTC deficiency, the urea cycle is blocked, so accumulated carbamoyl phosphate is **shunted into the de novo pyrimidine synthesis pathway**. This causes: 1. Increased carbamoyl aspartate formation 2. Increased dihydroorotate production 3. Increased orotate (orotic acid) production 4. Massive urinary orotic acid excretion (up to 1000× normal) This is the **hallmark biochemical finding** of OTC deficiency and is used diagnostically. ### Why Each Distractor Is Wrong | Distractor | Reason | | --- | --- | | **Option 1 (CORRECT)** | Carbamoyl phosphate accumulation is shunted into pyrimidine synthesis, directly explaining orotic acid elevation. | | **Option 2** | Ornithine transport defects are a separate disorder (hyperornithinemia-homocitrullinuria syndrome). OTC deficiency does not involve defective ornithine transport; the problem is that ornithine cannot be utilized even if present. | | **Option 3** | Ammonia does not directly inhibit pyrimidine degradation enzymes. The elevated orotic acid is due to **increased synthesis**, not decreased degradation. | | **Option 4** | Ammonia does not competitively inhibit orotate phosphoribosyltransferase (OPRT). The elevated orotic acid occurs upstream, at the level of orotate production, not at its conversion to orotidine monophosphate. | ### Clinical Correlation **Clinical Pearl:** The combination of: - Hyperammonemia - Normal blood glucose - Elevated plasma glutamine - **Markedly elevated urinary orotic acid** ...is pathognomonic for OTC deficiency and distinguishes it from other urea cycle defects (CPS I deficiency, argininosuccinate lyase deficiency, etc.), which do NOT produce orotic aciduria. **Mnemonic:** **OROTIC = OTC Rerouting Of Carbamoyl phosphate Into pyrimidine synthesis** ### Management Implications **Key Point:** Treatment includes: - Protein restriction - Nitrogen scavengers (sodium benzoate, sodium phenylbutyrate) - Arginine supplementation (bypasses the block) - Liver transplantation in severe cases [cite:Robbins 10e Ch 7; Harrison 21e Ch 297]